Phase II HD contract with new client worth >$500K
Updated : 07:00
IXICO plc
("IXICO" or the "Company")
Phase II Huntington's disease contract award with new client worth >$500K
IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces that it has been awarded a contract by a new US biopharmaceutical client to support its Phase II Huntington's disease (HD) clinical trial. HD is a rare condition of the nervous system that impacts the way people think, behave, and move.
IXICO's proprietary Trial Tracker platform will be used to collect, manage, and analyse MRI scans collected at 10 imaging centres across the world.
The purpose of the trial is to evaluate the safety and tolerability of the client's investigative therapy to determine appropriate dose levels in patients with HD recruited into the trial.
IXICO has been contracted as the specialist imaging vendor to provide advanced neuroimaging solutions involving structural MRI, as well as IXICO's patented LEAP, AI driven, analysis of the MRI scans.
The study is anticipated to generate more than $500K of revenues over twelve months.
Giulio Cerroni, Chief Executive Officer of IXICO, commented: "Huntington's disease is a devastating rare neurological condition with unmet medical needs. IXICO has worked on 16 HD clinical studies since 2007 and we are pleased to build further momentum in our mission to support our clients in identifying new insights into this challenging rare, neurodegenerative disease. Our technology services and AI data analytics enable clients to measure the impact of the trialled drugs with greater confidence and potentially unlock new insights into disease progression in support of much needed new drug development."
For further information please contact:
IXICO plc | +44 (0)20 3763 7498 | |||
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| |||
| ||||
Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0)20 7397 8900 | |||
Giles Balleny / Max Gould (Corporate Finance) |
| |||
Michael F Johnson / Russell Kerr (Sales) |
| |||
| ||||
Walbrook PR Ltd | +44 (0)20 7933 8780
| |||
Paul McManus / Lianne Cawthorne / | IXICO@walbrookpr.com | |||
Alice Woodings
| ||||
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.